Z
Zhimeng Biopharma
Biotech & Life Sciences · Huangpu, China · Founded 2017
Discovering and developing the most effective, safe and affordable drugs to improve the quality of life of patients in China and abroad MoreLess
Zhimeng Biopharma, founded in 2017 and based in Shanghai's Zhangjiang High Tech Park, is a biotech startup focused on developing medicines for chronic hepatitis B (CHB) and related liver diseases. The company aims to discover and develop the most effective, safe, and affordable drugs to improve the quality of life for patients both in China and globally. Zhimeng employs a comprehensive strategy to combat CHB by targeting the hepatitis B virus (HBV) with multiple approaches and restoring the host immune systems. The company serves patients suffering from chronic hepatitis B and other liver diseases, operating primarily in the pharmaceutical and biotech markets. Zhimeng's business model revolves around the research, development, and commercialization of innovative therapies. Revenue is generated through the successful development and sale of these drugs, as well as potential partnerships and licensing agreements. The company is also involved in early clinical development programs for drug candidates targeting neurological conditions such as epilepsy, pain, depression, and stroke. Keywords: chronic hepatitis B, liver diseases, biotech, pharmaceutical, innovative therapies, HBV, immune restoration, clinical trials, neurology, Shanghai.
Company overview
Zhimeng Biopharma company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- Huangpu, China
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 40.7
Valuation & funding
Zhimeng Biopharma funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Nov 2021 | $48M | $193M | Dyee Capital · Dawu Venture Capital · Advantech Capital · Fortune Venture | ↗ |
| SERIES AOther financing | Nov 2020 | $35M | $710M | Photon Fund · State Development & Investment Corporation (SDIC) · Oceanpine Capital | — |
| EARLY VCOther financing | Nov 2019 | $142M | $568M | Shenzhen Capital Group | ↗ |
Growth signals
Zhimeng Biopharma website traffic
Latest recorded traffic for Zhimeng Biopharma is 380 monthly website visits, down 35.6% over the last three months. Zhimeng Biopharma's team declined 12.5% over the past year.
Comparisons
Zhimeng Biopharma compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 Teitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases |
Aarhus, Denmark | Operational | 25 | $31M | $123M |
 AstronauTxSmall-molecule therapeutics targeting astrocytes for neurodegenerative diseases |
Reading, United Kingdom | Operational | |||
 CSPC Pharmaceutical GroupCSPC Pharmaceutical Group is a pharmaceutical group in China |
Shijiazhuang, China | Operational | |||
 WaveBreakSmall-molecule therapeutics for neurodegenerative diseases |
Cambridge, United Kingdom | Operational | |||
 FreeOx BiotechAdvancing Stroke Care through Innovation and Precision Medicine |
Barcelona, Spain | Operational | |||
 COMPASS PathwaysPsilocybin-based therapies for treatment-resistant mental health conditions |
London, United Kingdom | Operational | |||
 Rewind TherapeuticsFirst-in-class remyelinating therapies for myelin-related diseases |
Belgium, United States | Operational | |||
 AudioCure PharmaPharmaceutical company with a focus on hearing impairments |
Berlin, Germany | Operational |
Talent graph
Zhimeng Biopharma's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Zhimeng Biopharma has talent and traffic
team presence
In the news
Latest news about Zhimeng Biopharma
Recent press, funding announcements, and product moves mentioning Zhimeng Biopharma — open to read from the original sources.
Market sentiment
What the market is saying about Zhimeng Biopharma
An AI-synthesized read of the highest-engagement posts about Zhimeng Biopharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zhimeng Biopharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.